‘Global Defibrillators Market Worth $12.07bn In 2020’ Says Visiongain Report

30 August 2018
Pharma

Visiongain’s new report Global Defibrillators Market Forecast 2017 - 2026: External Defibrillators, Implantable Cardioverter Defibrillators, Transvenous ICD, Subcutaneous ICD, Single-Chamber ICD, Dual-Chamber ICD, Cardiac Resynchronization Therapy Defibrillators (CRT-D), Manual External Defibrillators, Automated External Defibrillators, Wearable Cardioverter Defibrillators indicates that the Global Defibrillators Market will see $12.07bn in spending in 2020.

The global defibrillators market is expected to grow at a CAGR of 5.3% from 2016-2020 and CAGR of 5.1% from 2020-2026. The market is expected to grow at a CAGR of 5.2% from 2016 to 2026. The market is estimated at $9.84bn in 2016, $12.07bn in 2020, and $16.29bn in 2026.

The lead analyst of the report said: “The world defibrillators market is expected to experience a significant growth over the forecast period. The main drivers for the growth include rapid growth in aging population, development of technologically advanced defibrillators, huge burden of cardiovascular diseases, increasing adoption of AEDs in public access markets, and supportive government authorities.
However, lack of awareness about sudden cardiac arrest, issues related to the use of defibrillator devices (external and implantable), and unfavourable healthcare reforms in the U.S. are some of the key factors restraining the growth of this market. In addition to this, increasing pricing pressure on market players and frequent product recalls pose major challenges to defibrillator manufacturers. During the course of the forecast period, more companies are expected to expand their operations into developing economies. ”
The 180 page report contains 75 tables and 93 charts that add visual analysis in order to explain the developing trends within the Global Defibrillators Market. Visiongain provides revenue forecasts for the period 2017-2026 as well as qualitative analyses for the leading products of this market: External Defibrillators, Implantable Cardioverter Defibrillators, Transvenous ICD, Subcutaneous ICD, Single-Chamber ICD, Dual-Chamber ICD, Cardiac Resynchronization Therapy Defibrillators (CRT-D), Manual External Defibrillators, Automated External Defibrillators and Wearable Cardioverter Defibrillators.

Visiongain also breaks down this market by end users: Hospitals and Cardiac Centers, Pre-hospital Services, Public Access, Home Care and Other End Users.

The 180 page report offers market forecasts and analysis for 13 leading national markets, the rest of Europe, the rest of APAC and rest of the world market. In addition, the report contains a dedicated leading companies’ chapter covering companies leading the field in the defibrillators market.

The Global Defibrillators Market Forecast 2017 - 2026: External Defibrillators, Implantable Cardioverter Defibrillators, Transvenous ICD, Subcutaneous ICD, Single-Chamber ICD, Dual-Chamber ICD, Cardiac Resynchronization Therapy Defibrillators (CRT-D), Manual External Defibrillators, Automated External Defibrillators, Wearable Cardioverter Defibrillators report will be of value to anyone who wants to better understand the Defibrillators market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Defibrillators industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read